Tisento Therapeutics
Clinical trials sponsored by Tisento Therapeutics, explained in plain language.
-
New hope for MELAS: Long-Term safety trial of zagociguat begins
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a daily tablet called zagociguat in people with MELAS, a rare genetic disease that affects energy production and can cause strokes. About 44 participants who finished a previous study will take the drug for an extended period, with clin…
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated May 03, 2026 16:27 UTC
-
New drug trial offers hope for rare MELAS fatigue and brain fog
Disease control OngoingThis study tests an experimental drug called zagociguat in 43 adults with MELAS, a rare genetic disease that causes strokes, fatigue, and thinking problems. Participants take either 15 mg, 30 mg, or a placebo daily for 12 weeks. The goal is to see if the drug reduces fatigue and …
Phase: PHASE2 • Sponsor: Tisento Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC